<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>25043229</identifier>
<setSpec>1885-1398</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Esplugues, Juan Vicente</dc:author>
<dc:author>Calvet, Xavier</dc:author>
<dc:description xml:lang="en">This consensus document reviews the evidence on the evaluation of biological drugs. The main conclusions of the group are: a) the current evidence on biological comparisons is based on indirect comparisons and is generally unreliable and with important methodological limitations. Therefore, b) it is considered necessary to amend the regulatory directives in the sense of strongly favoring randomized non-inferiority studies comparing face to face the new biological treatment with current standards, avoiding trials versus placebo, c) A key element in this process will be determined by consensus among regulatory agencies, scientific societies, the pharmaceutical industry and health authorities regarding the clinical differences that should be considered relevant in each of the conditions tested.</dc:description>
<dc:type>Consensus Development Conference</dc:type>
<dc:language>es</dc:language>
<dc:subject>Comparaciones indirectas</dc:subject>
<dc:subject>Non inferiority studies</dc:subject>
<dc:subject>Fármacos biológicos</dc:subject>
<dc:subject>Estudios de no inferioridad</dc:subject>
<dc:subject>Biologic drugs</dc:subject>
<dc:subject>Indirect comparisons</dc:subject>
<dc:date>2014 Nov-Dec </dc:date>
<dc:title xml:lang="en">How to compare biologic drugs.</dc:title>
<dc:publisher>Reumatologia clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
